Goldman Sachs
OPRX icon

Goldman Sachs’s OptimizeRx OPRX Stock Holding History

Goldman Sachs’s Portfolio OPRX Stock Details OPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$601K Sell
105,037
-253,406
-71% -$1.46M ﹤0.01% 5579
2026
Q1 		$2.25M Buy
358,443
+231,429
+182% +$2.15M ﹤0.01% 4436
2025
Q4 		$1.56M Sell
127,014
-9,450
-7% -$154K ﹤0.01% 4801
2025
Q3 		$2.8M Buy
136,464
+87,518
+179% +$1.39M ﹤0.01% 4182
2025
Q2 		$661K Sell
48,946
-2,061
-4% -$22.5K ﹤0.01% 4989
2025
Q1 		$442K Sell
51,007
-12,016
-19% -$73.4K ﹤0.01% 5260
2024
Q4 		$306K Buy
63,023
+29,798
+90% +$167K ﹤0.01% 5484
2024
Q3 		$256K Sell
33,225
-3,230
-9% -$28.7K ﹤0.01% 5370
2024
Q2 		$365K Buy
36,455
+21,985
+152% +$241K ﹤0.01% 5001
2024
Q1 		$176K Buy
14,470
+1,104
+8% +$16K ﹤0.01% 5147
2023
Q4 		$191K Sell
13,366
-30,985
-70% -$297K ﹤0.01% 5167
2023
Q3 		$345K Sell
44,351
-27,404
-38% -$298K ﹤0.01% 4831
2023
Q2 		$1.03M Sell
71,755
-13,334
-16% -$190K ﹤0.01% 4324
2023
Q1 		$1.24M Buy
85,089
+48,133
+130% +$805K ﹤0.01% 4224
2022
Q4 		$621K Sell
36,956
-22,188
-38% -$384K ﹤0.01% 4738
2022
Q3 		$876K Sell
59,144
-48,456
-45% -$958K ﹤0.01% 4604
2022
Q2 		$2.95M Buy
107,600
+28,966
+37% +$858K ﹤0.01% 3696
2022
Q1 		$2.96M Buy
78,634
+56,261
+251% +$2.49M ﹤0.01% 3874
2021
Q4 		$1.39M Sell
22,373
-48,527
-68% -$3.68M ﹤0.01% 4567
2021
Q3 		$6.07M Buy
70,900
+5,280
+8% +$331K ﹤0.01% 3191
2021
Q2 		$4.06M Sell
65,620
-23,527
-26% -$1.2M ﹤0.01% 3532
2021
Q1 		$4.35M Buy
89,147
+80,404
+920% +$3.88M ﹤0.01% 3256
2020
Q4 		$272K Sell
8,743
-48,608
-85% -$1.19M ﹤0.01% 4936
2020
Q3 		$1.2M Buy
+57,351
New +$985K ﹤0.01% 3952
2019
Q2 		– Sell
-27,193
Closed -$346K – 5294
2019
Q1 		$346K Buy
+27,193
New +$354K ﹤0.01% 4569

Other funds holding OPRX

WCA
Whetstone Capital Advisors Shawnee Mission, Kansas $380M AUM 20.01% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

Goldman Sachs's OPRX Position: Q2 2026 in Review

Goldman Sachs reduced its OptimizeRx (OPRX) stake by 71% in Q2 2026, selling an estimated $1.46M and leaving 105,037 shares worth $601K. The position accounts for ﹤0.01% of the portfolio, ranked #5579.

Goldman Sachs first reported a position in OPRX in Q1 2019 and has held it in 25 quarters since. The position peaked at $6.07M in Q3 2021. 113 funds tracked by Wall St. Rank hold OPRX as of Q2 2026.

  • Goldman Sachs held 105,037 shares of OptimizeRx worth $601K as of Q2 2026.
  • Goldman Sachs sold 253,406 OptimizeRx shares in Q2 2026, an estimated $1.46M.
  • OptimizeRx made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5579 holding.
  • Goldman Sachs first reported a position in OptimizeRx in Q1 2019 and has held it in 25 quarters since.
  • Goldman Sachs's OptimizeRx position peaked at $6.07M in Q3 2021.
  • 113 funds tracked by Wall St. Rank held OptimizeRx as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.